(USD M) | Mar'21 | Jun'21 | Sep'21 | Dec'21 | Mar'22 | Jun'22 | Sep'22 | Dec'22 | Mar'23 | Jun'23 | Sep'23 | Dec'23 | Mar'24 | Jun'24 | Sep'24 | Dec'24 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
LTM Revenue % growth | 835.9 578.9% | 1,240.1 361.5% | 1,569.0 290.3% | 1,901.7 222.5% | 2,543.3 204.3% | 3,051.9 146.1% | 2,629.8 67.6% | 3,147.2 65.5% | 3,604.2 41.7% | 4,068.0 33.3% | 5,467.9 107.9% | 5,861.9 86.3% | 6,536.0 81.3% | 7,233.3 77.8% | 8,216.8 50.3% | 9,177.6 56.6% |
LTM NOPAT % growth | (369.9) N/A | (401.8) 8.6% | (535.0) 33.1% | (547.2) 2.3% | (554.6) 1.4% | (588.6) 6.1% | (559.8) (4.9%) | (581.2) 3.8% | (542.6) (6.6%) | (443.4) (18.3%) | (318.8) (28.1%) | (243.5) (23.6%) | (25.8) (89.4%) | 37.8 N/A | 48.3 27.8% | 44.8 (7.3%) |
Discount rate | 8.3% | 8.4% | 8.5% | 8.4% | 9.3% | 7.9% | 8.8% | 7.6% | 9.0% | 9.5% | 9.7% | 9.7% | 10.4% | 10.6% | 10.2% | 10.7% |
Earnings Power Value (EPV) | (4,474.1) | (4,789.3) | (6,331.5) | (6,498.5) | (5,996.0) | (7,421.1) | (6,347.0) | (7,613.9) | (6,024.0) | (4,651.8) | (3,288.5) | (2,513.8) | (248.5) | 357.7 | 475.2 | 419.6 |
Enterprise Value (EV) | 1,225.6 | 1,833.5 | 1,370.8 | 14.5 | 467.0 | (1,649.3) | (1,882.2) | (2,004.0) | (1,221.9) | (1,332.4) | (2,036.7) | (67.9) | 1,180.2 | 1,113.5 | 2,677.1 | 1,890.8 |
Market-Implied Value of Growth (MIVoG) | 5,699.8 | 6,622.7 | 7,702.4 | 6,513.0 | 6,463.0 | 5,771.8 | 4,464.7 | 5,609.9 | 4,802.1 | 3,319.4 | 1,251.7 | 2,446.0 | 1,428.6 | 755.8 | 2,201.9 | 1,471.3 |
EPV as % of EV | (365.0%) | (261.2%) | (461.9%) | (44,664.2%) | (1,283.8%) | 449.9% | 337.2% | 379.9% | 493.0% | 349.1% | 161.5% | 3,704.9% | (21.1%) | 32.1% | 17.8% | 22.2% |
MIVoG as % of EV | 465.0% | 361.2% | 561.9% | 44,764.2% | 1,383.8% | (349.9%) | (237.2%) | (279.9%) | (393.0%) | (249.1%) | (61.5%) | (3,604.9%) | 121.1% | 67.9% | 82.2% | 77.8% |
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Explore the best low P/E stocks to buy in 2025, featuring top companies trading at low P/E ratios.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
As of Dec 31, 2024, Oscar Health, Inc.'s Earnings Power Value is approximately $419.6M.
As of Dec 31, 2024, Oscar Health, Inc.'s Enterprise Value (EV) estimates at $1,890.8M.
As of Dec 31, 2024, Oscar Health, Inc.'s Net operating profit after tax (NOPAT) is approximately $44.8M.